Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Venrock
BioCentury | Jan 11, 2025
Finance
Metsera, Maze will play canary in the IPO coal mine
Pair of Arch, Ra portfolio companies file to list on NASDAQ
BioCentury | Nov 23, 2024
Finance
ATB’s €54M series A among largest ever in Belgium
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | Nov 5, 2024
Discovery & Translation
New frontiers in extracellular protein degradation
Six papers detail improved ways to degrade cell-surface cancer proteins through the lysosome
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Oct 3, 2024
Emerging Company Profile
Mythic: Enhancing ADC payload delivery using pH engineering
Biotech engineers its antibody-drug conjugates to unbind their target upon internalization, recycling it back to the cell surface to recruit more ADCs
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | Sep 10, 2024
Deals
Deals report: Roivant sets up Pulmovant to advance hypertension therapy
Plus: Candid joining two VC-backed start-ups to focus on autoimmune bispecifics, and updates from Eli Lilly, Haya, Genetic Leap and more
BioCentury | Sep 10, 2024
Emerging Company Profile
Candid: Bispecifics for autoimmunity, leveraging Chinese oncology innovation
Ken Song’s post-RayzeBio venture pulled together two licensing deals, an M&A transaction and three financings totaling $370M
BioCentury | Aug 9, 2024
Finance
Public equity report: Symbiotic Capital launches with $600M credit fund
Plus: TG Therapeutics’ $250M term loan, and public raises by Tenax, MindMed
Items per page:
1 - 10 of 521